Could Adjuvant Chemotherapy Improve Prognosis for Cervical Cancer Patients with Elevated Pretreatment Serum Squamous-Cell Carcinoma Antigen?

Zhen Yuan, Dongyan Cao, Ying Zhang, Keng Shen, Jiaxin Yang, Mei Yu, Huimei Zhou Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People’s Republic of ChinaCorrespondence: Dongyan Cao;...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuan Z (Author), Cao D (Author), Zhang Y (Author), Shen K (Author), Yang J (Author), Yu M (Author), Zhou H (Author)
Format: Book
Published: Dove Medical Press, 2021-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Zhen Yuan, Dongyan Cao, Ying Zhang, Keng Shen, Jiaxin Yang, Mei Yu, Huimei Zhou Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, People’s Republic of ChinaCorrespondence: Dongyan Cao; Ying Zhang Email caodongyanpumch@sina.com; zhangyingpumch@163.comObjective: The aim of this study was to explore whether adjuvant chemotherapy could improve prognosis for cervical cancer patients with elevated pretreatment serum squamous-cell carcinoma antigen (SCC-Ag).Methods: Propensity-score matching and inverse probability of treatment weighting (IPTW) were used to ensure balanced groups for patients with (arm A) and without adjuvant chemotherapy (arm B). All patients were treated between January 2012 and December 2014 at a single center. Study outcomes were disease-free survival (DFS) and overall survival (OS).Results: In total, 81 patients were included in this study. By propensity-score matching, 35 patients were included in each group (arm A and arm B). Median follow-up was 60 months in arm A and 66 months in arm B. Overall, 85.7% of patients in arm A and 71.4% of those in arm B received adjuvant radiotherapy. DFS and OS curves were similar between arms A and B (P=0.971 and 0.633, respectively). With IPTW, arm A was not associated with prognosis in terms of DFS (HR 0.946, 95% CI 0.237– 3.784; P=0.938) or OS (HR 1.020, 95%CI 0.357– 2.913; P=0.970).Conclusion: For patients with elevated pretreatment SCC-Ag, adjuvant chemotherapy was not found to improve prognosis. Also, a considerable proportion of these patients had postoperative indications for adjuvant radiotherapy. For these cervical cancer patients with elevated pretreatment SCC-Ag, the choice of radical hysterectomy and adjuvant chemotherapy should be prudent.Keywords: adjuvant chemotherapy, cervical cancer, oncologic outcomes, serum squamous-cell carcinoma antigen
Item Description:1179-1594